| KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer J Cicenas, K Kvederaviciute, I Meskinyte, E Meskinyte-Kausiliene, ... Cancers 9 (5), 42, 2017 | 278 | 2017 |
| The CDK inhibitors in cancer research and therapy J Cicenas, M Valius Journal of cancer research and clinical oncology 137, 1409-1418, 2011 | 275 | 2011 |
| Roscovitine in cancer and other diseases J Cicenas, K Kalyan, A Sorokinas, E Stankunas, J Levy, I Meskinyte, ... Annals of translational medicine 3 (10), 2015 | 268 | 2015 |
| The potential role of Akt phosphorylation in human cancers J Cicenas The International journal of biological markers 23 (1), 1-9, 2008 | 206 | 2008 |
| Highlights of the latest advances in research on CDK inhibitors J Cicenas, K Kalyan, A Sorokinas, A Jatulyte, D Valiunas, A Kaupinis, ... Cancers 6 (4), 2224-2242, 2014 | 151 | 2014 |
| KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma J Cicenas, L Tamosaitis, K Kvederaviciute, R Tarvydas, G Staniute, ... Medical oncology 34, 1-11, 2017 | 150 | 2017 |
| Kinases and cancer J Cicenas, E Zalyte, A Bairoch, P Gaudet Cancers 10 (3), 63, 2018 | 135 | 2018 |
| Non-coding RNAs in glioma R Rynkeviciene, J Simiene, E Strainiene, V Stankevicius, J Usinskiene, ... Cancers 11 (1), 17, 2018 | 122 | 2018 |
| JNK, p38, ERK, and SGK1 inhibitors in cancer J Cicenas, E Zalyte, A Rimkus, D Dapkus, R Noreika, S Urbonavicius Cancers 10 (1), 1, 2018 | 102 | 2018 |
| Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2 J Cicenas, P Urban, V Vuaroqueaux, M Labuhn, W Küng, E Wight, ... Breast Cancer Research 7, 1-8, 2005 | 78 | 2005 |
| Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients J Cicenas, P Urban, W Küng, V Vuaroqueaux, M Labuhn, E Wight, ... European Journal of Cancer 42 (5), 636-645, 2006 | 75 | 2006 |
| The Aurora kinase inhibitors in cancer research and therapy J Cicenas Journal of cancer research and clinical oncology 142, 1995-2012, 2016 | 57 | 2016 |
| Metabolomics in pancreatic cancer biomarkers research J Tumas, K Kvederaviciute, M Petrulionis, B Kurlinkus, A Rimkus, ... Medical Oncology 33, 1-7, 2016 | 51 | 2016 |
| Multi-kinase inhibitors, AURKs and cancer J Cicenas, E Cicenas Medical Oncology 33, 1-11, 2016 | 50 | 2016 |
| Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts U Weissenstein, MJ Schneider, M Pawlak, J Cicenas, ... Proteomics 6 (5), 1427-1436, 2006 | 45 | 2006 |
| The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner V Stankevicius, L Kunigenas, E Stankunas, K Kuodyte, E Strainiene, ... Biochemical and biophysical research communications 484 (4), 726-733, 2017 | 35 | 2017 |
| Proteomic identification of FLT3 and PCBP3 as potential prognostic biomarkers for pancreatic cancer M Ger, A Kaupinis, M Petrulionis, B Kurlinkus, J Cicenas, A Sileikis, ... Anticancer research 38 (10), 5759-5765, 2018 | 27 | 2018 |
| JNK inhibitors: is there a future? J Cicenas MAP Kinase 4 (1), 2015 | 18 | 2015 |
| SGK1 in cancer: Biomarker and drug target J Cicenas, E Meskinyte-Kausiliene, V Jukna, A Rimkus, J Simkus, ... Cancers 14 (10), 2385, 2022 | 17 | 2022 |
| Quantitative proteomic analysis of anticancer drug RH1 resistance in liver carcinoma M Ger, A Kaupinis, A Nemeikaite-Ceniene, J Sarlauskas, J Cicenas, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1864 (2), 219-232, 2016 | 17 | 2016 |
Mindaugas ValiusHead of Proteomics Center, Life Sciences Center, Vilnius University在 bchi.vu.lt 的电子邮件经过验证
